Materialise NV has invested in additional medical production capacity in US. The move strengthens the reliability of Materialise Mimics® Innovation Suite as a medical backbone solution for healthcare professionals. The Mimics Innovation Suite is being used in hospitals, and other clinical settings and has driven expansion of Materialise operations in the U.S. market. The expansion further enables a complete range of powerful 3D surgical planning options to support patient-specific treatment, and the capacity to expediently provide anatomical models in the US market.
By providing virtual planning software linked with fully integrated Materialise 3D print services, clinicians and surgeons can use vital supplemental information to simulate or evaluate the best options for patient-specific treatment, and facilitate clear communication with patients, co-workers and/or surgical teams. Materialise HeartPrint, which is registered as a class 1 medical device in the US, aids cardiovascular specialists in helping plan patient care and select the necessary tools to treat complex cases such as congenital heart surgery or aortic aneurysm interventions.
Materialise continues to evolve its Mimics Innovation Suite capabilities and has made a new version of software that caters to clinicians with a desire to use 3D printing in their case planning.
“Unlike many existing products which only work with a limited number of the 3D printing solutions, Materialise’s 510(k) cleared software connects to all 3D printing technologies. We are excited to expand our capacity, technology breadth and increase our responsiveness to the needs of clinicians. It is this focus that led our expansion in the U.S.,” stated Bryan Crutchfield, Managing Director at Materialise USA.